# Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

> **NCT05536297** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 278 (actual)

## Conditions studied

- Geographic Atrophy
- Age-Related Macular Degeneration

## Interventions

- **DRUG:** avacincaptad pegol

## Key facts

- **NCT ID:** NCT05536297
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-26
- **Primary completion:** 2025-04-10
- **Final completion:** 2025-04-10
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536297, "Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05536297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*